Charles River Laboratorie

Q2 FY2026 EarningsQ2 FY26 results beat consensus across the board: revenue $1.00B vs. $0.98B expected, and non-GAAP EPS $3.02 vs. $2.73 expected. Organic growth turned positive (0.1%) for the first time since Q3 2023, driven by a strengthening demand environment in the DSA segment (net book-to-bill at a 4-year high). Management raised FY26 non-GAAP EPS guidance to $11.15–$11.45, significantly above the prior midpoint, reflecting operational outperformance and improving biopharma R&D spending trends.